PRESCRIBING INFORMATION MEDICAL INFO REQUEST FAQs PATIENT SITE Connect with Us 2025 Medicare Part D Updates: Encourage Your Patients to Enroll Learn more (English)Learn more (Spanish) For your adult patients with CKD associated with T2D Your move can change ...
对于T2DM合并CKD患者来说,早期管理的短期可视目标是蛋白尿的降低,长期目标是心肾事件的降低。管理手段方面,以nsMRA为例,其能够显著改善蛋白尿水平,并带来显著且一致的心肾获益。如在FIDELITY研究和FIGARO-DKD研究中,非奈利酮显著降低UACR达32%,且作用持续整个研究期间[3,4]。中介分析进一步表明,非奈利酮降低UACR可...
Guidelines from the American Diabetes Association and Kidney Disease: Improving Global Outcomes recommend finerenone for patients with type 2 diabetes and CKD at high risk for CKD progression and cardiovascular events despite use of recommended therapies....
For each patient, the presence of CKM conditions was summed for the following comorbidities: CKD, HF and/or DM. The bars represent 95% CIs around each treatment effect point estimate. CV, cardiovascular; DM, diabetes mellitus. Full size image Incidences of any serious adverse event were lower...
In July of 2021, Bayer received FDA approval for finerenone, a first in its class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated in adults with chronic kidney disease (CKD) associated with T2DM. Finerenone was shown to reduce the risk of cardiovascular death, s...
38,39 Elevations in serum potassium and the incidence of investigator-reported AEs related to hyperkalemia with finerenone, however, remained similar between the Hispanic and non-Hispanic patient subgroups in the current analysis. Although this trial enrolled a large number of patients with CKD, the...
finerenone is already FDA approved for the treatment of adult patients with type 2 diabetes–associated chronic kidney disease (CKD) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, sustained estimated glomerular filtration rate decline, and ...
Finerenone was first approved by the FDA in July 2021 to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, CV death, non-fatal myocardial infarction (MI), and hospitalization for HF in adults with chronic kidney disease...
Review Published:14 August 2024 Volume 86, pages 882–889, (2024) Cite this article EndocrineAims and scopeSubmit manuscript Abstract Overactivation of mineralocorticoid receptors occurs in cardiorenal diseases. Many patients with type 2 diabetes often progress to chronic kidney disease (CKD) and requir...
In short, the pathogenesis of CKD in the patient with DM2 involves multiple converging mechanisms, including poor metabolic control as a trigger and potential accelerator of the process, as well as MR-mediated inflammation and fibrosis and abnormal hemodynamics that, once established, are self-perpetu...